Evidence map›Paper›PMID 38607340›Full record

ArticleJAMA2024

Non-High-Density Lipoprotein Cholesterol Levels From Childhood to Adulthood and Cardiovascular Disease Events.

Feitong Wu, David R Jacobs, Stephen R Daniels, Mika Kähönen, Jessica G Woo, Alan R Sinaiko, Jorma S A Viikari, Lydia A Bazzano, Julia Steinberger, Elaine M Urbina and 5 more

Open access · hybridAbstract read
In one paragraph

Article in JAMA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
19.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 4 countries.

Feitong WuBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
David R JacobsDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis.
Stephen R DanielsDepartment of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora.
Mika KähönenFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Jessica G WooDivision of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Alan R SinaikoUniversity of Minnesota Medical School, Minneapolis.
Jorma S A ViikariDepartment of Medicine, University of Turku, Turku, Finland.
Lydia A BazzanoDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Julia SteinbergerDepartment of Pediatrics, University of Minnesota School of Medicine, Minneapolis.
Elaine M UrbinaThe Heart Institute, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Alison J VennMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Olli T RaitakariCentre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland.
Terence DwyerMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Markus JuonalaDepartment of Medicine, University of Turku, Turku, Finland.
Costan G MagnussenBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Cincinnati Children's Hospital Medical Center · USTurku University Hospital · FIUniversity of Minnesota · USUniversity of Tasmania · AUBaker Heart and Diabetes Institute · AUTampere University · FITulane University · USUniversity of Colorado Denver · USUniversity of Melbourne · AUUniversity of Minnesota Medical Center · USUniversity of Turku · FI

Funding

PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Edward L Melanson · 1995 to 2026
$32.6M
Childhood CV Risk and Adult CVD Outcomes: an International Long-term Follow-upR01HL121230 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI BURNS, TRUDY L, CHEN, WEI · 2015 to 2019
$13.3M
EVOLUTION OF CARDIOVASCULAR RISK WITH NORMAL AGINGR01AG016592 · NIA · TULANE UNIVERSITY OF LOUISIANA · PI CHEN, WEI · 2000 to 2015
$11.7M
INSULIN AND BLOOD PRESSURE CHANGE DURING ADOLESCENCER01HL052851 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SINAIKO, ALAN R. · 1995 to 2007
$5.0M
EPIDEMIOLOGY OF CAROTID ARTERY ATHEROSCLEROSIS IN YOUTHR01HL054730 · NHLBI · UNIVERSITY OF IOWA · PI DAVIS, PATRICIA HELEN · 1995 to 2008
$4.7M
Lifespan Cardiovascular Risk Exposures and Alzheimer-related brain health: Bogalusa Heart StudyRF1AG041200 · NIA · TULANE UNIVERSITY OF LOUISIANA · PI BAZZANO, LYDIA, CARMICHAEL, OWEN T. · 2019 to 2022
$4.2M
Supplemental Funding Request for RF1 AG062309 Early life glycemic status and Alzheimer's disease neuroimaging markers in middle age: the Bogalusa Heart StudyR01AG062309 · NIA · TULANE UNIVERSITY OF LOUISIANA · PI BAZZANO, LYDIA, CARMICHAEL, OWEN T. · 2019 to 2023
$3.9M
ARTERIAL ENDOTHELIAL FUNCTION--AN EPIDEMIOLOGIC STUDYR01HL061857 · NHLBI · UNIVERSITY OF IOWA · PI BURNS, TRUDY L · 2005 to 2008
$3.0M
VASCULAR CALCIUM--AN EPIDEMIOLOGIC STUDYR01HL048050 · NHLBI · UNIVERSITY OF IOWA · PI MAHONEY, LARRY T · 1992 to 2004
$3.0M
Cardiovascular Risk and Insulin Resistance: Age 7-40R01DK072124 · NIDDK · UNIVERSITY OF MINNESOTA · PI STEINBERGER, JULIA · 2007 to 2011
$3.0M
GENETIC EPIDEMIOLOGY OF CHILDHOOD OBESITYR01HD029569 · NICHD · UNIVERSITY OF IOWA · PI BURNS, TRUDY L · 1992 to 2003
$2.6M
A novel research infrastructure enabling life-course studies of healthy agingR33AG057983 · NIA · TULANE UNIVERSITY OF LOUISIANA · PI BAZZANO, LYDIA · 2020 to 2022
$2.4M
NHLBI NIH HHS N01 HC055025NHLBI NIH HHS R01 HL002942NHLBI NIH HHS R01 HL034659NHLBI NIH HHS R01 HL048050NHLBI NIH HHS R01 HL052851NHLBI NIH HHS R01 HL054730NHLBI NIH HHS R01 HL061857NHLBI NIH HHS R01 HL062394NHLBI NIH HHS R01 HL121230NIAID NIH HHS R01 AI176494NIA NIH HHS R01 AG016592NIA NIH HHS R01 AG062309NIA NIH HHS R03 AG060619NIA NIH HHS R33 AG057983NIA NIH HHS RF1 AG041200NICHD NIH HHS R01 HD029569NICHD NIH HHS R01 HD032194NICHD NIH HHS R01 HD069587NICHD NIH HHS R03 HD047247NICHD NIH HHS R03 HD062783NIDDK NIH HHS R01 DK072124NIDDK NIH HHS R21 DK085363NIEHS NIH HHS R01 ES021724NIGMS NIH HHS R01 GM028719
6 · The paper itself

Abstract

Importance: Elevated non-high-density lipoprotein cholesterol (non-HDL-C; a recommended measure of lipid-related cardiovascular risk) is common in children and increases risk of adult cardiovascular disease (CVD). Whether resolution of elevated childhood non-HDL-C levels by adulthood is associated with reduced risk of clinical CVD events is unknown. Objective: To examine the associations of non-HDL-C status between childhood and adulthood with incident CVD events. Design, Setting, and Participants: Individual participant data from 6 prospective cohorts of children (mean age at baseline, 10.7 years) in the US and Finland. Recruitment took place between 1970 and 1996, with a final follow-up in 2019. Exposures: Child (age 3-19 years) and adult (age 20-40 years) non-HDL-C age- and sex-specific z scores and categories according to clinical guideline-recommended cutoffs for dyslipidemia. Main Outcomes and Measures: Incident fatal and nonfatal CVD events adjudicated by medical records. Results: Over a mean length of follow-up of 8.9 years after age 40 years, 147 CVD events occurred among 5121 participants (60% women; 15% Black). Both childhood and adult non-HDL-C levels were associated with increased risk of CVD events (hazard ratio [HR], 1.42 [95% CI, 1.18-1.70] and HR, 1.50 [95% CI, 1.26-1.78] for a 1-unit increase in z score, respectively), but the association for childhood non-HDL-C was reduced when adjusted for adult levels (HR, 1.12 [95% CI, 0.89-1.41]). A complementary analysis showed that both childhood non-HDL-C levels and the change between childhood and adulthood were independently associated with the outcome, suggesting that from a preventive perspective, both childhood non-HDL-C levels and the change into adulthood are informative. Compared with those whose non-HDL-C levels remained within the guideline-recommended range in childhood and adulthood, participants who had incident non-HDL-C dyslipidemia from childhood to adulthood and those with persistent dyslipidemia had increased risks of CVD events (HR, 2.17 [95% CI, 1.00-4.69] and HR, 5.17 [95% CI, 2.80-9.56], respectively). Individuals who had dyslipidemic non-HDL-C in childhood but whose non-HDL-C levels were within the guideline-recommended range in adulthood did not have a significantly increased risk (HR, 1.13 [95% CI, 0.50-2.56]). Conclusions and Relevance: Individuals with persistent non-HDL-C dyslipidemia from childhood to adulthood had an increased risk of CVD events, but those in whom dyslipidemic non-HDL-C levels resolve by adulthood have similar risk to individuals who were never dyslipidemic. These findings suggest that interventions to prevent and reduce elevated childhood non-HDL-C levels may help prevent premature CVD.

Indexed as

Cardiovascular DiseasesCholesterol, LDLDyslipidemiasAdolescentAdultChildChild, PreschoolCholesterolFemaleFinlandHeart Disease Risk FactorsHumansIncidenceMaleProspective StudiesUnited StatesCholesterolCholesterol, LDL

Identifiers

PMID38607340
PMCPMC11151142
OpenAlexW4394749587

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.